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Abstract: Celiac disease (CD) is a severe genetic autoimmune disorder, affecting about one in 100
people, where the ingestion of gluten leads to damage in the small intestine. Diagnosing CD is
quite complex and requires blood tests and intestinal biopsy examinations. Controversy exists
regarding making the diagnosis without biopsy, due to the large spectrum of manifesting symptoms;
furthermore, small-intestinal gastroscopy examinations have a relatively complex management in
the pediatric population. To identify novel molecular markers useful to increase the sensitivity and
specificity in the diagnosis of pediatric CD patients, the expression levels of two key autophagy
executor genes (ATG7 and BECN1) and their regulatory validated miRNAs (miR-17 and miR-30a,
respectively) were analyzed by relative quantitative real-time-PCR on a cohort of confirmed CD
patients compared to age-related controls. Among the investigated targets, the non-parametric
Mann–Whitney U test and ROC analysis indicated the highest significant association of BECN1 with
CD status in the blood, while in intestinal biopsies, all of the investigated sequences were positively
associated with CD diagnosis. Nomogram-based analysis showed nearly opposite expression trends
in blood compared to intestine tissue, while hierarchical clustering dendrograms enabled identifying
CD and control subgroups based on specific genes and miRNA expression signatures. Next, using
an established in vitro approach, through digested gliadin administration in Caco-2 cells, we also
highlighted that the modulation of miR-17 endogenous levels using enriched exosomes increased the
intracellular autophagosome content, thereby altering the autophagic status. Altogether, these results
highlighted novel molecular markers that might be useful to increase the accuracy in CD diagnosis
and in molecular-based stratification of the patients, further reinforcing the functional involvement of
the regulation of the autophagy process within a digestive and autoimmune-related disorder as CD.
Keywords: microRNA; autophagy; celiac disease molecular markers
1. Introduction
Celiac disease (CD), also referred to as celiac sprue and gluten-sensitive enteropathy, is a chronic
systemic autoimmune disease of the small intestine. This disease results from an immune response, in
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genetically-susceptible individuals, to ingested dietary gluten and its related peptides in the form of
wheat, barley and rye cereals and other environmental factors [1]. Small intestinal biopsy histology
has long been considered an essential step for CD diagnosis. However, gastrointestinal endoscopy
is invasive, costly and associated with risks for the patients. Researchers have therefore explored
the possibility of CD diagnosis without endoscopy or biopsy analyses. In particular, European
Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) guidelines and other
contributions proposed that in children and adolescents with signs or symptoms suggestive of CD
and high anti-transglutaminase antibodies with levels ten-times higher compared to normal ones, the
probability of villous atrophy is high, thus allowing CD diagnosis without biopsies’ examination [2,3].
Liquid biopsies based on circulating cell-free tumor DNA (ctDNA) or circulating miRNAs
(cmiRNAs) hold great clinical promise for investigations in cancer and autoimmune disorders [4].
Several studies have uncovered possible roles for miRNA regulation in autoimmune diseases,
specifically rheumatoid arthritis and systemic lupus erythematosus [5]. In another subset of
inflammatory bowel diseases, it was reported that miRNAs’ expression signatures differentiate Crohn’s
disease from ulcerative colitis (UC) [6]. Among these, miR-29a is overexpressed in the blood of UC
patients, and it is also a potential non-invasive biomarker for colorectal cancer [7]. Benderska and
colleagues [8] demonstrated that miR-26b overexpression at the intestinal level could serve as a
biomarker to distinguish between ulcerative colitis-associated carcinogenesis and sporadic cancer
types, showing that miRNAs can be useful in patients’ stratification.
The regulation of gene expression in the intestinal epithelium is complex and controlled by
different signaling pathways that regulate the balance between proliferation and differentiation,
processes altered in pathologies, such as CD [9]. To date, only a few studies have reported the
identification of miRNAs as potential epigenetic biomarkers in CD [10]. Among these, Buoli Comani
and colleagues [11] demonstrated that miRNAs and their gene targets showed an altered expression
in duodenal mucosa and in plasma of CD pediatric patients, and these alterations could be different
from adult ones. Specifically, it was reported that high levels of miR-449a targeted and reduced
both NOTCH1 and KLF4 expression in the small intestine of CD patients, leading to an impaired
differentiation and maturation of goblet cells [12]. Recently, a subset of deregulated miRNAs (i.e.,
miR-31-5p, miR-192-3p, miR-194-5p, miR-551a, miR-551b-5p, miR-638 and miR-1290) was identified in
CD patients with different clinical phenotypes compared with non-CD subjects, and in particular, it
was reported that miR-192-3p levels were modulated by gliadin peptides in vitro [13]. Furthermore,
it was documented that chemokine C-X-C motif ligand 2 (CXCL2) and NOD2 showed significantly
increased mRNA and protein levels in Marsh 3C CD patients and a significant inverse correlation with
the regulatory miR-192-5p. In addition, alterations in CXCL2 and NOD2, FOXP3, miR-192-5p and
miR-31-5p expression were triggered by gliadin exposure in CD patients [14].
All eukaryotic cells are able to digest their cytoplasmic content through different processes that
undergo the general term autophagy (from the Greek words “self” and “to eat”). Autophagy includes
different forms of digestive pathways, namely macroautophagy, microautophagy, chaperone-mediated
autophagy and non-canonical autophagy. Generally, the term autophagy refers to macroautophagy:
this process depends on specialized autophagy-related proteins (Atg) and is able to digest different
targets, such as organelles, large aggregates of proteins and microorganisms [15]. Autophagy plays
also a key role in direct microorganism and virus clearance, in control of inflammation through the
inhibition of the inflammasome, antigen presentation, T cell homeostasis and secretion of immune
mediators [16]. Autophagy impairment is crucial in several diseases, in particular proteinopathies,
such as Alzheimer’s [17], Parkinson’s [18] and Huntington’s [19]. Autophagy plays also a crucial
role in the pathogenesis of several inflammatory diseases: in particular, genetic polymorphisms
in autophagy regulatory genes ATG16L and IRGM conferred a strong predisposition to Crohn’s
disease development [20]. Furthermore, SNPs within the autophagy-regulatory ULK1 gene have been
identified to increase susceptibility to Crohn’s disease [21]. On the other hand, limited knowledge is
available on the role of the effect of the modulation of the autophagy process in the CD context.
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To this purpose, the expression of two main executor genes involved in the canonical autophagy
process (i.e., ATG7 and BECN1) and their negative confirmed regulators, respectively miR-17 and
miR-30, were investigated in a cohort of pediatric CD patients. Atg7 protein has different functions
in autophagosomal biogenesis, acting primary as an E1-like ligase, which conjugates Atg5 to Atg12,
a necessary step for the formation of a functional autophagosome. In addition, Atg7 converts Atg8
(LC3) from an immature, cytosolic form to a mature autophagosomal membrane protein by adding a
phosphatidylethanolamine group. Genetic deletion of ATG7 causes an overt loss of autophagy, proving
that the gene product is necessary for some autophagic functions [22].
BECN1 was the first identified autophagy gene [23], and it encodes a protein, Beclin 1, interacting
with several cofactors (Atg14L, UVRAG, Bif-1, Rubicon, Ambra1, HMGB1, nPIST, VMP1, SLAM, IP3R,
PINK and survivin) to regulate in turn the lipid kinase Vps-34 protein and promote the formation of
Beclin 1-Vps34-Vps15 core complexes, thereby inducing autophagy. Furthermore, Beclin 1 coordinately
regulates the autophagy and membrane trafficking involved in several physiological and pathological
processes [24]. Beclin 1 knockout mice die in early embryogenesis, showing that autophagy is clearly
necessary for mammalian survival [25].
miR-17 has been identified as the first miRNA with oncogenic potential and therefore named
“oncomiR-1” [26]. It is strongly expressed in embryonic stem cells and has essential roles in vital
processes like cell cycle regulation, proliferation and apoptosis, representing a promising biomarker
and a therapeutic target tool [27]. The importance of miR-17 for fundamental biological processes is
underscored by the fact that miR17-deficient mice are neonatally lethal. Recently, miR-17 was identified
in the context of aging, turning out to be the first “longevimiR”, extending the lifespan of transgenic
miR-17-overexpressing mice [28]. Several studies reported the specific role of miR-17 in modulating
the autophagy process in different contexts [29–32]. The other investigated microRNA, miR-30a, is
a member of the miR-30 family [33]. Dysregulation of miR-30a was correlated with several types of
malignant tumors [34]. In most of the cancers, miR-30a functions as a tumor suppressor by regulating
the corresponding target genes [35]. Noticeably, miR-30a was involved in the regulation of the Beclin
1-mediated autophagy process in different cells [36–39].
In this paper, novel potential molecular markers (i.e., autophagy-related genes and their regulatory
miRNAs) were primary investigated in blood and in intestinal biopsies of pediatric patients with
active CD compared with non-CD subjects matched for age and sex, highlighting an advantage for CD
diagnosis. In addition, we reported using an in vitro model that the modulation of a specific miRNA’s
expression can induce differences in the cellular autophagic status.
2. Results
2.1. Identification of Autophagy Genes/miRNAs Associated with CD
To identify novel molecular markers useful to increase the sensitivity and specificity in pediatric
CD patients’ diagnosis, the expression levels of two main autophagy genes and their regulatory
miRNAs were analyzed. Specifically, BECN1 and miR-30a, ATG7 and miR-17 were investigated.
To this purpose, relative quantitative real-time-PCR was performed in blood and in intestinal biopsies
derived from exploratory cohorts of pediatric CD patients with active disease compared with controls,
as described in the Materials and Methods. Notched box-and-whisker plots of the expression levels
of the analyzed markers in both tissues were reported (Figure 1). Among the investigated targets,
miR-17 showed the greatest variability in the blood in CD patients and controls (Figure 1A), while,
in intestinal biopsies ATG7 showed the widest range of variations (Figure 1B). In Figure S1, scatterplots
highlight the general distribution of the analyzed samples.
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Figure 1. Expression profiles of autophagy-related genes and miRNAs in the investigated tissues. 
Notched box-and-whisker plot of the expression values obtained by real-time PCR from blood (A) or 
intestinal biopsies (B) of celiac disease (CD) patients and controls. In the Y axes, the relative 
quantitative expression (RQ) values are reported. Outliers (circles) and far-out values (squares) are 
indicated. Differently, in intestinal biopsies, ATG7 showed the highest expression profile variability 
in both groups (Figure 1B). 
To assess the presence of statistically-significant differences in the expression levels between CD 
patients and controls, the non-parametric Mann–Whitney U test was performed. Differences were 
considered statistically significant when the p-value was less than 0.05. In blood, only BECN1 showed 
statistically-significant differences between the two analyzed groups (p-value = 0.0189). Conversely, 
in intestinal biopsies, all of the investigated targets showed statistically-significant differences 
between CD and control subjects (Table 1). 
Table 1. Association of autophagy-related genes’ and miRNAs’ relative expression with CD status. 
Tissue Gene/miRNA Z-Score p-Value 
Blood 
ATG7 2.13 0.2585 
BECN1 2.34 0.0189 * 
miR-17 1.13 0.2557 
miR-30a 1.51 1.1310 
Intestinal biopsy 
ATG7 2.41 0.0159 * 
BECN1 2.48 0.0129 * 
miR-17 2.09 0.0365 * 
miR-30a 2.16 0.0302 * 
Z-scores and p-values obtained with the Mann–Whitney U test. The asterisks indicate a  
statistically-significant association with CD (p-value < 0.05). 
2.2. Bioinformatics Performance of the Investigated Targets as Potential CD Biomarkers 
To further assess the diagnostic capability of the investigated autophagy-related genes/miRNAs 
to distinguish between CD and control subjects, the receiver operating characteristics (ROC) analysis 
was performed (Table 2). 
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Notched box-and-whisker plot of the expression values obtained by real-time PCR from blood (A)
or intestinal biopsies (B) of celiac disease (CD) patients and controls. In the Y axes, the relative
quantitative expression (RQ) values are reported. Outliers (circles) and far-out values (squares) are
indicated. Differently, in intestinal biopsies, ATG7 showed the highest expression profile variability in
both groups (Figure 1B).
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Tissue Gene/miRNA Z-Score p-Value
Blood
ATG7 2.13 0.2585




ATG7 2.41 0.0159 *
BECN1 2.48 0.0129 *
miR-17 2.09 0.0365 *
miR-30a 2.16 0.0302 *
Z-scores and p-values obtained with the Mann–Whitney U test. The asterisks indicate a statistically-significant
association with CD (p-value < 0.05).
2.2. Bioinformatics Performance of the Investigated Targets as Potential CD Biomarkers
To further assess the diagnostic capability of the investigated autophagy-related genes/miRNAs
to distinguish between CD and control subjects, the receiver operating characteristics (ROC) analysis
was performed (Table 2).
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Table 2. ROC curve analysis of the association of autophagy-related genes and miRNAs relative
expression with CD status.
Tissue Gene/miRNA AUC C.I. 95% p-Value Sensitivity Specificity
Blood
ATG7 0.603 0.46–0.73 0.1723 78.26 47.06
BECN1 0.683 0.54–0.79 0.012 * 65.22 74.29
miR-17 0.605 0.46–0.73 0.1822 34.78 97.06
miR-30a 0.632 0.49–0.75 0.0754 56.52 67.65
Intestinal biopsies
ATG7 0.697 0.55–0.81 0.007 * 64.00 69.23
BECN1 0.703 0.55–0.82 0.0068 * 88.00 57.69
miR-17 0.671 0.52–0.79 0.0274 * 56.00 84.62
miR-30a 0.677 0.53–0.80 0.0238 * 72.00 69.23
Area under the curve (AUC), confidence intervals (C.I., at 95%), sensitivity and specificity percentage values are
reported. The asterisks indicate a statistically-significant association with CD status (p-value <0.05).
In blood, the BECN1 ROC curve revealed a fair diagnostic property (AUC = 0.683; p = 0.012).
The sensitivity and specificity values associated with this curve were 65.22% and 74.29%, respectively.
In intestinal biopsies, similar levels within a fair range of sensitivity and specificity were reported
for ATG7, BECN1, miR-17 and miR-30a, associated with a statistically-significant probability of
CD condition.
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Figure 2. Classification tree obtained using the relative quantitative expression values (numbers over 
each box) of the analyzed genes (ATG7 and BECN1) and miRNAs (miR-17 and miR-30a) in blood. CD 
patients are indicated in blue, controls in red. Color tonalities are related to the composition of each 
subgroup. Resulting subgroups are highlighted by capital letters. 
To determine whether the investigated genes/miRNAs were able to effectively distinguish CD 
and control subjects and to eventually stratify CD patients, a supervised multivariate analysis was 
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Figure 2. Classification tree obtained using the relative quantitative expression values (numbers over
each box) of the analyzed genes (ATG7 and BECN1) and miRNAs (miR-17 and miR-30a) in blood. CD
patients are indicated in blue, controls in red. Color tonalities are related to the composition of each
subgroup. Resulting subgroups are highlighted by capital letters.
To deter ine hether the investigated genes/ iR As ere able to effectively distinguish CD
and control subjects and to eventually stratify C patients, a supervised ultivariate analysis as
conducted. Initially, a classification tree as created on the relative quantitative expression values
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detected in the blood of CD patients and controls. As reported in Figure 2, two main branches were
apically originated by evaluating only miR-17 expression cut-off levels (i.e., inferior/superior of an
18.19-fold expression difference compared to the average of the control samples, used as an internal
calibrator): the former classified 32/47 (68.09%) subjects as controls, while the latter 8/9 (88.89%) as
CD; evaluating the relative contribution of the some of the other investigated targets (i.e., BECN1
and ATG7), 12 additional homogeneously-represented subgroups were obtained, as indicated by
capital letters (A–N). In particular, D, F and M subgroups homogeneously classified 16/23 CD patients
(69.56%). In detail, Subgroup G was composed of three CD patients and one control, while two CD
patients and one control belonged to Subgroup I. Conversely, Subgroups A, B, H and L homogenously
classified 28/33 controls (84.85%).
A classification tree was also created for samples derived from intestinal biopsies. As reported in
Figure 3, the apical ramification was determined by a BECN1 expression cut-off value of a 0.71-fold
expression difference compared to the average of control subjects (internal calibrator). Then, differently
from blood tissue, all of the investigated markers contributed to the next classification roots: in
particular, 11 subgroups were obtained, again indicated by the capital letters. Five of them (i.e., B, E, G,
H and L) homogeneously classified 22/25 CD patients (88%). Similarly, A, D and M grouped 19/24
controls (79.16%), whereas Subgroups F and I were composed of two controls and one CD patient.
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co position of each subgroup. Resulting subgroups are highlighted by capital letters.
ext, an unsupervise analysis as con ucte e ploying relative gene expression ata to test
their perfor ance in classification. In particular, the classification tree algorithm was assayed
to calculate the probability of each subject to be correctly classified in accordance ith the initial
clinical-based diagnosis. sing the expression levels of the genes/ i s detected in the blood, only
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four subjects (i.e., 10, 29, 36 and 56) were misclassified (Table S1). In the case of intestinal biopsies, only
three subjects were misclassified (i.e., 7, 15 and 49), as indicated in Table S2.
To determine the relative contribution of each gene/miRNA in improving the CD diagnostic
performance, a naive Bayesian nomogram analysis was performed. Relative expression profiles of
the investigated targets and their associated probabilities to identify the CD condition were reported
(Figure 4).
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Figure 4. Nomogram tool to predict CD status in the blood specimens. The nomogram (lower graph)
was created considering the relative quantitative expression values of the analyzed genes/miRNAs
(upper graphs). The red line evidences the portion of the curves (on the right side of each) that confers
a high probability (p > 0.8) to correctly classify a CD condition.
The expression profiles were represented according to their relative positive influence in
determining an increased probability of CD identification, specifically set on p > 0.8. In blood
samples, as reported in Figure 4, the expression trends were nearly monotonic. An increase in
the expression levels of one or more of these markers was therefore nearly proportional to the increase
in probability of a correct CD identification (right portions of the curves defined by the red vertical
line, corresponding to the highlighted portion of the nomogram of probability). As shown in Figure 5,
in intestinal biopsies, ATG7 showed an opposite nearly-monotonic trend compared to the blood tissue.
Differently, BECN1 and the investigated miRNAs exhibited very complex curves, with higher scores of
the defined probability (p > 0.8) associated with the CD status in correspondence with low relative
expression values.
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2.3. In Vitro Modulation of miR-17 Affects Autophagic Status
Next, Caco-2 cells were employed to mimic the induction of a celiac-like condition by direct
digested gliadin administration to the cells. Gliadin peptides were previously subjected to a partial
enzymatic digestion as described [40]. Digested gliadin uptake was firstly assayed by indirect
immunofluorescence (Figure 6).
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As expected, Caco-2 cells rapidly bound digested gliadin at their membranes (soon after 30 min)
and finally (from 4 h) internalized a large amount of the extracellular protein content. Then, at different
times after digested gliadin administration (i.e., t0, 4, 24, 48 and 72 h post-treatment (p.t.)), total
RNA from Caco-2 cells was extracted, quantified and subjected to relative expression analysis by
real-time PCR, specifically for miR-17, miR-30a, ATG7 and BECN1. After normalization, miR-17
and miR-30a displayed downregulated expression trends, while, as a direct consequence, ATG7 and
BECN1 were upregulated. In particular, ATG7 and its negative regulator miR-17 showed more marked
and functionally-correlated differences (Figure S2). Immunoblotting analysis confirmed the induced
increase in Atg7 and Beclin 1 protein expression, following digested gliadin administration, again
more relevant for the former protein (Figure 7).
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Figure 7. Immunoblotting analysis of autophagy proteins after digested gliadin administration in
Caco-2 cells. (A) Caco-2 cells were incubated with digested gliadin (10 mg/mL) for different times.
Then, proteins were extracted and assayed for expression of Atg7 and Beclin 1 proteins. Molecular
weights (kDa) are reported; (B) Densitometric analysis was obtained after normalization with BACT
expression and referred to untreated (t0) cells. p.t., post-treatment.
Next, a modulation of miR-17 expression, to affect the Atg7 protein profile, was performed in
Caco-2 cells, using exosomes as cargo vehicles of the specific miRNA. Exosomes were primary isolated
from different human cancer cells (HeLa, Caco-2, T98G) using Total Exosome Isolation (from cell culture
media) as described in the Materials and Methods. Total exosomal RNAs were isolated and assayed
by Real-time PCR for miR-17 expression. Exosomes showing less intra-organelle content of miR-17
were employed for the next experiments; specifically, T98G-derived exosomes highlighted the most
reduced content of miR-17 (real-time PCR quantitative relative miR-17 expression, using HeLa miR-17
levels as the internal calibrator, were: HeLa = 1 ± 0.11; Caco-2 = 0.77 ± 0.21; T98G = 0.36 ± 0.19).
T98G-derived exosomes were also visualized by electron microscope (Figure 8), showing a relative
overall maintenance of their integrity after isolation procedures.
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3. Discussion
In this study, novel biomarkers related to the autophagy process were investigated in blood and
in intestinal biopsies of pediatric patients with active celiac disease (CD) compared with non-CD
subjects matched for age and sex. CD is an immune-mediated systemic disorder of the small intestine
elicited by gluten and related prolamins in genetically-susceptible individuals and characterized by
the presence of different clinical manifestations [1–3,42].
As already stated, the autophagy process was primarily investigated due to its relative importance
in host defense against intra- and extra-cellular pathogens, metabolic syndromes, immune cell
homeostasis, antigen processing and presentation, as well as for its role in autoimmune disorders [43].
Our study was conducted on a cohort of pediatric CD patients and control subjects, clinically classified
as described in the Material and Methods. All of the samples were analyzed through real-time
PCR for the relative expression of two essential autophagic genes (ATG7 and BECN1) and their
functionally-related miRNAs (miR-17 and miR-30a).
As introduced before, Beclin 1 and Atg7 are key proteins implicated in autophagy, respectively in
the nucleation phase and in autophagosome elongation [15]. However, among the ATG genes, ATG6 or
BECN1 is relatively unique in its not being “autophagy-specific”. In fact, recent findings indicated that
Beclin 1 is a multifaceted protein that governs additional processes, such as endocytosis, phagocytosis
and cytokinesis. More generally, Beclin 1 is involved in development, differentiation, stress adaptation,
inflammation, tumorigenesis, aging and cell death [44]. All of these processes have in common the
regulation of membrane flux and their specific corresponding controls, where the autophagic and
non-autophagic functions of Beclin 1 can be determined by the binding of specific interactors that
define its subcellular localization and trafficking [45]. On the other hand, it is widely documented that
the expression levels of Beclin 1 are tightly controlled, since many diseases are associated with Beclin 1
malfunction or deficiency, and therefore, Beclin 1 is considered a valuable target for the treatment of
distinct pathologies [46]. Atg7 is a protein playing a central role in the canonical autophagy process,
specifically in the elongation of the autophagosome membranes. Recent works have suggested that
autophagy can occur using multiple variant mechanisms, bypassing seemingly essential proteins,
including Atg7. In fact, a dispensable function of Atg7 was reported, replaced by TRIM31 in Chron’s
disease [47]; other authors suggested alternative routes to macroautophagy without a significant
contribution of Atg5 and Atg7 [48]. Furthermore, mice models of experimentally-induced colitis
with intestinal epithelial deletion of Atg7 showed reduced size of granules and decreased levels of
lysozyme in Paneth cells, suggesting that this protein was dispensable for gut immune homeostasis
and had no effect on susceptibility [49]. Conversely, other autophagy-related genes (ATG16L1 and
IRGM) seemed to play important roles for autophagy in maintaining intestinal homeostasis, and the
overall dysfunction of autophagy resulted in being a major risk factor for the onset of chronic intestinal
inflammation [20].
In general, alternative mechanisms of autophagy are growing in which Atg proteins appear
to be dispensable under some circumstances. This might reflect a still unraveled complexity of the
autophagy process. We have also to consider that, while much of our understanding of autophagy
mechanisms comes from in vitro systems using either yeast or mammalian cell lines, the significance
of autophagy in pathology is mostly derived from experimental animal models. Using animals to
model defective autophagy mechanisms may, however, introduce an additional layer of complexity in
our attempts to understand cell type-specific defects in autophagy [50].
Among all of the miRNAs that play a role in autophagy regulation, miR-30a and miR-17 were
selected because of their experimental validation as negative regulators of defined molecular steps
within the autophagic process. Particularly, miR-30a negatively regulated BECN1 expression resulting
in a decrease of the autophagy activity. Moreover, it was demonstrated that treatment of different cancer
cell lines with the miR-30a mimic and antagomir molecules could respectively decrease and increase
BECN1 expression [51]. A similar approach was used on T98G glioblastoma cells to demonstrate that
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miR-17 negatively regulated ATG7 expression, thus contributing to an overall downregulation of the
autophagic process [29].
In relation to the clinically-established diagnostic criteria in CD [3], the tissues assayed in the
present study were blood and intestinal biopsies. In the former tissue, the expression levels of
BECN1 differed significantly between CD patients and controls. The area under the ROC curve
confirmed the levels of expression of BECN1 as a marker that can fairly distinguish between the two
diagnostic groups. The differences in the levels of expression were confirmed by the ROC analyses,
and the area under the ROC curve highlighted the capability to significantly cluster patients and
controls. Differently, considering intestinal biopsies, the expression of all investigated molecular
targets gave statistically-significant performance in distinguishing between patients affected by CD. To
determine whether the investigated genes/miRNAs were able to effectively stratify the CD patients, a
supervised multivariate analysis was conducted. Classification trees were used based on the decision
tree learning model [52]. In blood, miR-17 constituted the first decision node of the tree, determining
together with BECN1 expression levels the first subgroup of CD patients. The other subgroups are
determined by the algorithm taking into account all of the targets excluding miR-30a. Altogether, CD
patients homogeneously classified were 16/23 (69.50%), suggesting that blood guaranteed a discreet
performance in CD patients’ stratification. The classification tree obtained for intestinal biopsies
homogeneously classified 22/25 CD patients (88%) into five subgroups using the expression values of
BECN1 (as the apical node), ATG7 and their negative regulators, miR-17 and miR-30a. Subsequently,
the ability of the algorithm to correctly classify all of the subjects according to the initial clinical-based
diagnosis was evaluated. The number of subjects correctly classified was 52/56 (92.86%) in the case of
blood and 46/49 (93.88%) analyzing the intestinal biopsy specimens. Then, nomograms were created
for both investigated tissues using the Orange software [53] to evaluate the relative contribution of each
gene/miRNA in determining an increase in the CD diagnostic probability performance. A nomogram
is a dynamic supervised statistical tool used to analyze continuous and categorical variables together,
adopting a heuristic problem solving approach [54]. The algorithm calculates for each continuous
variable a score and a probability associated with the disease/physiological state. This tool was used
also in other pathological contexts, i.e., glioblastoma [55,56] in prostate, breast, ovarian, renal cell
carcinoma and melanoma to stratify patients and to find specific molecular signatures [57]. In blood,
a high rate of CD patients’ probability was primarily determined by the increase of miR-17, followed by
ATG7, miR-30a and BECN1 expression levels. Although the Mann–Whitney U test and ROC analyses
did not identify any miRNAs as able to distinguish among CD patients and controls, according to the
blood-predicted nomogram, miR-17 played a relevant role in increasing the CD likelihood. In intestinal
biopsies, the originated nomogram pointed to a decreased expression trend for ATG7 associated with
CD diagnostic probability, while BECN1 and the two miRNAs exhibited complex and non-linear
expression profiles.
Based on the described evidence, a parsimonious interpretation model of the expression results is
proposed (Figure 10).
As shown, CD onset would correspond with an autophagy impairment in epithelial cells of the
intestine, as revealed by the ATG7 and BECN1 downregulation nomogram trends. The decrease in
the expression of miR-17 and miR-30a could be explained as the result of a compensatory mechanism
triggered by this pathological loss of homeostasis in the autophagic process, in order to counteract the
downregulation of the autophagy-related one. The miR-30a and miR-17 decreasing expression trend
could be further mediated by the release of these miRNAs as a cargo within exosomes, thus in part
explaining the high levels revealed by blood nomograms. Finally, in this tissue, the increase of ATG7
and BECN1 relative expression could be due to another compensatory process to maintain autophagy
homeostasis after the exosome-mediated release of miR-17 and miR-30a from the epithelial cells.
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Lastly, the in vitro results using the Caco-2 cell model, widely adopted in CD studies [58,59] and
challenged with a direct digested gliadin administration, provided a possible mechanistic view of
the regulatory effects of miRNAs, specifically miR-17, on the expression of a key autophagic gene
as ATG7. Similar to our previous results [29], we showed that even only modulating intracellular
miR-17 levels, this can significantly alter the autophagic status of the cells. In the results herein
reported, anti-miR17-enriched exosomes, obtained through a specific electroporation protocol, induced
a prominent increase in acridine orange red positive vesicles. These vesicles had an acidic content,
due to the spectral property of the fluorescent dye [60], and additionally, microscope visualization
indicated the presence of undigested materials, typical of autophagosomes. We can also speculate
that the activation of the autophagy process might counteract the gliadin cellular toxicity, leading to a
possible digestion of these exogenous proteins. With this regard, additional in vitro experiments to
confirm this hypothesis are ongoing (Comincini, personal communication).
Certainly, these results need further investigations to confirm the diagnostic power of the
investigated autophagic markers. In particular, additional autophagy-related genes and their
regulatory miRNAs should be included in a larger cohort of CD patients and controls to strengthen
the results obtained in this study, since the statistical resolution of data mining and machine learning
analyses, i.e., classification trees and nomograms, depends on the size of the analyzed cohort. Of note,
it was demonstrated that the autophagy process could have a functional role within this pathological
condition. Indeed, expression levels of key autophagic genes (ATG7 and BECN1) and their regulatory
miRNAs (miR-17 and miR-30a) in the blood and intestinal biopsies can give molecular signatures
useful to classify and stratify CD patients. This positive feature made these genes and miRNAs
interesting candidates as novel non-invasive biomarkers in the CD field. Furthermore, according to
the interpretative model and with the in vitro results, exosomes content might be deeply investigated,
thus determining a profile of endogenous and circulating miRNAs in the blood of CD patients, with
the potentiality to regulate in different areas important cellular processes, like autophagy.
4. Materials and Methods
4.1. Investigated Celiac Patients and Controls
Pediatric patients were enrolled in collaboration with the Pediatric Auxology Unit and the
Pediatric Surgery Unit of the Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
Policlinico San Matteo (Pavia, Italy) over the last two years. This study (project identification code:
31140/2014, date of approval: 16 December 2013) was approved by the Ethical Committee “Comitato
Etico Area di Pavia” (Pavia, Italy), and written informed consent was obtained from the parents of
all of the subjects. The cohort of subjects submitted to CD screening was divided into two groups,
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as described in Table S3. CD patients were enrolled for the concomitant presence of symptoms
(anemia, short stature, gastrointestinal symptoms given by malabsorption). Positive serological tests
and histological analysis of the biopsies confirmed the CD diagnosis. Control patients were referred
to clinicians for other reasons not related to CD. Some of them underwent upper gastrointestinal
endoscopy for other clinical purposes, such as gastroesophageal reflux, esophageal varices, gastritis or
H. pylori infection. The exclusion criteria were dysmorphic syndromes, chromosomal abnormalities
and chronic conditions causing growth retardation. A total of 105 specimens were collected, specifically
56 blood samples and 49 intestinal biopsies. Blood samples were collected from 33 controls and 23
untreated CD patients, whereas biopsies were collected from 24 controls and 25 untreated CD patients,
divided into the Marsh 3B and 3C pathological grading. Blood (3 mL for each sample) was collected
in EDTA tubes, whereas duodenal specimens (5–10 mm3 for each biopsy) were collected in 1.5 mL
of TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Both types of tissues were stored at −80 ◦C until
RNA extraction.
4.2. Real-Time PCR Expression Analysis
Total RNA was extracted from blood and biopsies tissues with TRIzol reagent according to the
manufacturer’s instructions. Before RNA extraction, biopsies were homogenized with Tissue Ruptor
(Qiagen, Hilden, Germany). RNA quantification was performed using the Quant-it RNA Assay
(Invitrogen). miRNAs’ cDNA was obtained using a sequence-specific hairpin-primer and amplified
using the TaqMan MicroRNA Assays kit (Applied Biosystems, Foster City, CA, USA). ATG7 and BECN1
cDNA were obtained using random hexamers primers (Applied Byosystems, Foster City, CA, USA ) as
reported in Comincini et al. [29]. ATG7 (TaqMan Assay ID Hs00893766_m1), BECN1 (TaqMan Assay ID
Hs01007018_m1), miR-17 (TaqMan Assay ID 478447_mir) and miR-30a (TaqMan Assay ID 479448_mir)
were amplified with TaqMan Universal Master Mix II, no UNG (Applied Biosystems). Real-time PCR
was performed using 5 ng of each cDNA and using the MiniOpticon Real-Time PCR System (Bio-Rad,
Hercules, CA, USA) platform. Samples were analyzed in duplicate and subjected to 40 amplification
cycles of 95 ◦C for 15 min and 60 ◦C for 1 min. All data were normalized to ACTB (TaqMan Assay ID
Hs01060665_g1) and relative quantification with the 2−∆∆Ct method [61] was employed to calculate
relative changes in gene expression using an internal calibrator (control sample) obtained calculating
the mean of all of the controls. All of the relative quantification values were checked for the presence
of outliers and far-out values. The samples with relative quantification values very far from the
mean were analyzed a second time, and the outliers were verified as real. As the deletion of outliers
is a controversial practice especially for relatively small cohorts, all of the statistical analyses were
performed including also the samples with outliers and far-out values.
4.3. Digested Gliadin In Vitro Assay
Caco-2 cells from the American Type Culture Collection (ATCC) were cultured and maintained in
DMEM (Euroclone, Milano, Italy) supplemented with 10% FBS, 100 units/mL penicillin, 0.1 mg/mL
streptomycin and 1% L-glutamine and kept at 37 ◦C in a 5% CO2 air atmosphere. Gliadin from
wheat (Sigma, St. Louis, MO, USA) was digested as described [40] to a final concentration of 1 g/mL.
In detail, gliadin was firstly dissolved in 500 mL 0.2 N HCl for 2 h at 37 ◦C with 1 g of pepsin (Sigma).
The resultant peptic digest was further digested by the addition of 1 g trypsin (Sigma), after pH
adjustment to 7.4 using 2 N NaOH, and the solution was incubated at 37 ◦C for 4 h with vigorous
agitation. Finally, the mixture was boiled to inactivate enzymes for 30 min and stored at −20 ◦C.
For in vitro assays, digested gliadin (10 mg/mL) was firstly administered directly to Caco-2 cells in
suspensions (about (1–1.5) × 106) for 30 min at 37 ◦C, and then cells were distributed in multiwell
12-wells plates for different time intervals.
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4.4. Immunofluorescence and Immunoblotting Analysis
Immunofluorescence assays were performed similarly to [62]. In detail, primary antibody
anti-gliadin (Abcam, Cambridge, UK) was diluted 1:30 and used to trace the gliadin uptake and
internalization into vesicles. Species-specific Alexa Fluor 488 secondary conjugated antibody (1:100)
(Invitrogen) was then employed. Cells cultured on coverslips were washed three times with PBS and
fixed with 4% paraformaldehyde-PBS, pH 7.4, for 15 min at room temperature. Cells were incubated
for 1 h with primary antibody diluted in PBS + 5% non-fat milk powder (w/v). Cells were then
washed with PBS and incubated for 1 h with secondary antibody in PBS + 5% non-fat milk powder.
Coverslips were then washed three times with PBS and treated with ProLong Gold antifade reagent
with DAPI (Invitrogen) according to the manufacturer’s instructions and finally mounted onto glass
slides. Fluorescence signals were detected using a fluorescence light inverted microscope (Nikon
Eclipse TS100, Tokyo, Japan) with a 100× oil immersion objective. Western blot analysis was performed
using procedures previously described [63]. The following primary antibodies directed against the
antigens were used: Atg7 and Beclin 1 (1:1000, rabbit polyclonal, Cell Signaling, Danvers, MA, USA),
while ACTB (1:5000, mouse monoclonal, Cell Signaling) was used as the loading control in the Western
blots, as already reported [64].
4.5. Exosome Isolation, Visualization and Electroporation
Exosomes were isolated using Total Exosome Isolation (from cell culture media) (Invitrogen,)
according to the manufacture’s specification. In detail, assayed cells (HeLa, T98G, Caco-2) were
grown near to their confluence in 10 mL of complete DMEM medium supplemented with 10% of
Exosome Depleted FBS Qualified Origin (Invitrogen). Culture media were collected, and 5 mL of
Total Exosome Isolation reagent for Cell Culture were then added to the media and incubated at 4 ◦C
for 20 h. Then, exosomes were pelleted at 10,000 rpm for 60 min at 4 ◦C and finally resuspended in
0.5 mL of sterile ice-cold Dulbecco’s PBS. Half of each exosome’s preparations were used for RNA
extraction using TRIzol reagent. RNA was quantified (typically 2–6 ng for each isolation), subjected to
cDNA synthesis specific for miR-17 or miR-30a and then assayed in relative quantitative expression
by real-time PCR, using the above-reported conditions. Exosomes from T98G cells, showing the
lowest miR-17 expression levels, were selected for further experiments directly to modulate their
intravesicular content of miR-17 levels; these exosomes were then visualized by transmission electron
microscopy. In detail, 20 microliter drops of the isolated exosomes in D-PBS were placed on a Parafilm
(Sigma) sheet, and a 300-mesh nickel grid (covered with a Formvar-carbon film) was floated onto
the drops and allowed to stay for 5 min. The grids were rapidly blotted with filter paper and
negatively stained with a 2% phosphotungstic acid solution, pH 7.0, for 60 s, blotted on paper and
observed directly on a Zeiss EM900 electron microscope (Zeiss, Oberkochen, Germany) operating at
80 kV. Next, 100 microliters of exosomes in D-PBS were electroporated with 2.5 µM of each mimic
(premiR-17, Ambion #AM25576), antagomiR (antimiR-17, Ambion #AM17010) or without (mock). For
electroporation, the Neon Transfection System (Invitrogen) along with the Neon 100 µL kit (Invitrogen)
were used and adopting these physical parameters: voltage = 700 V, width = 10 ms, pulse = 10.
4.6. Acridine Orange Staining of Autophagic Vesicles
The direct visualization of acidic vesicles was performed using an acidotropic dye, i.e., acridine
orange (excitation/emission: 502/525 nm). Acridine orange was added at the final concentration
of 1 µg/mL in Caco-2 cultures 10 min before inverted microscope fluorescent visualizations. As already
documented [60], different intracellular vesicles emitted in the red range because of the protonation
of the dye caused by their acidic content. Autophagosomes and lysosomes can also be distinguished
according to their shape and size since the former are more heterogeneous and bigger in dimension [60].
An inverted fluorescence microscope (Eclipse Nikon TS100) was employed for live cell monitoring
using 40× magnification.
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4.7. Statistical Analysis
The MedCalc software 15.8 (https://www.medcalc.org/) was used to perform the Mann–Whitney
U test and the receiver operating characteristic (ROC) curve analysis. The Orange data mining software
(http://orange.biolab.si/) was used for the nomograms and the classification trees using a naive Bayes
learner/classifier. Differences were considered statistically significant when p < 0.05.
5. Conclusion
This study demonstrated that autophagy investigation could be promising at different levels in
celiac disease (CD) research. Indeed, expression levels of key autophagic genes (ATG7 and BECN1) and
miRNAs (miR-17 and miR-30a) in the peripheral blood and intestinal biopsies can fairly distinguish
between CD patients and controls. This positive feature made these genes and miRNAs interesting
candidates as novel non-invasive biomarkers in CD field, thus recommending further investigations
on larger cohorts to assess their potential diagnostic power and to find other interesting candidate
as biomarkers. Moreover, the present study highlighted a possible role of these autophagy targets in
CD patients’ stratification, especially at the bioptic level. In addition, the creation of nomograms as
supporting tools to assist in CD diagnosis, particularly in potential CD, seems to be clinically relevant.
Lastly, in vitro experiments, showed the possibility to increase autophagy through the modulation of
miR-17 levels using anti-miR17-enriched exosomes, with the aim to digest gliadin thus counteracting its
toxicity. In conclusion, it was demonstrated that genes and miRNAs involved in autophagy might have
a potential diagnostic utility for CD and for the creation of clinical predictive tools. Moreover, deeper
investigation on within this process and its modulation could be a promising strategy in developing
new CD treatments. Finally, although the complexity of this disease and its clinical management,
this study might present new interesting perspectives in CD diagnosis and therapy research.
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